Mannan/MUC-1 vaccine: Phase IIa started

PRR subsidiary CancerVac began an Australian Phase IIa trial in 20 patients. In March, PRR licensed IP covering the MUC1 protein for use in its Mannan-MUC1 fusion protein vaccine from Biomira Inc. (...